Leukemia and Lymphoma Society April 8, 2017 | Aurora, CO
Stop by and learn about how Archer® Blood Cancer NGS assays are purpose-built to identify key drivers in leukemia and lymphoma, enabling rapid identification of mutations for high-throughput laboratories.
Archer Blood Cancer assays
The Archer® FusionPlex® Kits are targeted next-generation sequencing assays that detect and identify fusions, point mutations and expression levels from RNA input.
The VariantPlex™ Core AML Kit was designed for superior coverage across key genes implicated in Acute Myeloid Leukemia (AML).
ArcherDX addresses the bottlenecks associated with using NGS by offering a robust platform for targeted sequencing applications.
Archer target enrichment assays utilize AMP chemistry to generate highly enriched sequencing libraries for comprehensive profiling of fusions, CNVs, SNVs and indels. Amplification from independent, unidirectional primers and universal molecular barcoded adapters permit identification of novel gene fusions and mutations with nucleotide-level resolution. Requiring only one intact primer-binding site, AMP chemistry is uniquely suited to amplify small, degraded fragments, enabling solid tumor mutation profiling from FFPE samples and liquid biopsies.
Archer’s easy-to-use, lyophilized kits generate sequencing-ready libraries from RNA, DNA, and liquid biopsy-derived ctDNA. Complemented by the Archer suite of assay design and bioinformatics analysis, Archer’s FusionPlex, VariantPlex and Reveal ctDNA assays facilitate complex mutation identification and discovery, while Immunoverse assays enable quantitative profiling of the expressed immune repertoire.
For Research Use Only. Not for use in diagnostic procedures.
Having trouble getting the documents using Chrome Browser? Make sure you're using the default zoom factor by pressing Control + 0 on a PC or Command + 0 on a Mac. Hover over the PDF in this window and the download button should appear in a black bar at the top.